[go: up one dir, main page]

AU2001287000A1 - Modified polypeptides stabilized in a desired conformation and methods for producing same - Google Patents

Modified polypeptides stabilized in a desired conformation and methods for producing same

Info

Publication number
AU2001287000A1
AU2001287000A1 AU2001287000A AU8700001A AU2001287000A1 AU 2001287000 A1 AU2001287000 A1 AU 2001287000A1 AU 2001287000 A AU2001287000 A AU 2001287000A AU 8700001 A AU8700001 A AU 8700001A AU 2001287000 A1 AU2001287000 A1 AU 2001287000A1
Authority
AU
Australia
Prior art keywords
conformation
protein
methods
desired conformation
producing same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001287000A
Inventor
Chafen Lu
Motomu Shimoaka
Timothy A. Springer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Childrens Hospital
Original Assignee
Immune Disease Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immune Disease Institute Inc filed Critical Immune Disease Institute Inc
Publication of AU2001287000A1 publication Critical patent/AU2001287000A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/26—Containing cys-cys disulfide bridge between nonadjacent cysteine residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention provides a method for stabilizing a protein in a desired conformation by introducing at least one disulfide bond into the polypeptide. Computational design is used to identify positions where crysteine residues can be introduced to form a disulfide bond in only one protein conformation, and therefore lock the protein in a given conformation. Accordingly, antibody and small molecule therapeutics are selected that are specific for the desired protein conformation. The invention also provides modified integrin I-domain polypeptides that are stabilized in a desired conformation. The invention further provides screening assays and therapeutic methods utilizing the modified integrin I-domains of the invention.
AU2001287000A 2000-09-01 2001-08-31 Modified polypeptides stabilized in a desired conformation and methods for producing same Abandoned AU2001287000A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22970000P 2000-09-01 2000-09-01
US60/229,700 2000-09-01
PCT/US2001/027227 WO2002018583A2 (en) 2000-09-01 2001-08-31 Modified polypeptides stabilized in a desired conformation and methods for producing same

Publications (1)

Publication Number Publication Date
AU2001287000A1 true AU2001287000A1 (en) 2002-03-13

Family

ID=22862353

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001287000A Abandoned AU2001287000A1 (en) 2000-09-01 2001-08-31 Modified polypeptides stabilized in a desired conformation and methods for producing same

Country Status (8)

Country Link
US (6) US7160541B2 (en)
EP (1) EP1315812B1 (en)
JP (1) JP5113314B2 (en)
AT (1) ATE448306T1 (en)
AU (1) AU2001287000A1 (en)
CA (1) CA2417432C (en)
DE (1) DE60140457D1 (en)
WO (1) WO2002018583A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2554965C (en) * 2004-02-19 2015-08-11 The Cbr Institute For Biomedical Research, Inc. Antibodies specific for activated conformation of lfa-1
US7081687B2 (en) * 2004-07-22 2006-07-25 Sprint Communications Company L.P. Power system for a telecommunications facility
US7240492B2 (en) * 2004-07-22 2007-07-10 Sprint Communications Company L.P. Fuel system used for cooling purposes
AU2005277547B2 (en) 2004-08-16 2011-08-25 Immune Disease Institute, Inc. Method of delivering RNA interference and uses thereof
US20070018182A1 (en) * 2005-07-20 2007-01-25 Goldeneye, Inc. Light emitting diodes with improved light extraction and reflectivity
US20090291048A1 (en) * 2005-10-25 2009-11-26 Baker Idi Heart And Diabetes Institute Holdings Limited Leukocyte-binding polypeptides and uses thereof
US8021668B2 (en) * 2005-12-12 2011-09-20 Immune Disease Institute, Inc. Integrin alpha L I domain mutants with increased binding affinity
WO2007127272A2 (en) * 2006-04-24 2007-11-08 The Cbr Institute For Biomedical Research Method of producing immunoliposomes and compositions thereof
WO2007127221A2 (en) * 2006-04-25 2007-11-08 Immune Disease Institute Inc. Targeted delivery to leukocytes using non-protein carriers
JP5396270B2 (en) * 2006-06-02 2014-01-22 プレジデント アンド フェロウズ オブ ハーバード カレッジ Protein surface remodeling
EP2030015B1 (en) * 2006-06-02 2016-02-17 President and Fellows of Harvard College Protein surface remodeling
US20120328628A1 (en) * 2006-07-07 2012-12-27 The Regents Of The University Of California Antibodies to conformationally trapped proteins
US20110112040A1 (en) * 2008-04-28 2011-05-12 President And Fellows Of Harvard College Supercharged proteins for cell penetration
US8877893B2 (en) * 2008-12-29 2014-11-04 Children's Medical Center Corporation Stabilized low affinity conformation of integrins for drug discovery
WO2010129023A2 (en) 2009-04-28 2010-11-11 President And Fellows Of Harvard College Supercharged proteins for cell penetration
LT3326645T (en) * 2010-10-25 2020-08-10 Biogen Ma Inc. Methods for determining differences in alpha-4 integrin activity by correlating differences in svcam and/or smadcam levels
WO2012139069A2 (en) * 2011-04-07 2012-10-11 Neotope Biosciences Limited Compositions and methods for treating diseases of protein aggregation involving ic3b deposition
WO2012149540A1 (en) 2011-04-28 2012-11-01 The Broad Institute Inc Inhibitors of histone deacetylase
CA2880117C (en) 2012-07-27 2021-04-06 The Broad Institute, Inc. Inhibitors of histone deacetylase
US9880179B2 (en) * 2013-02-05 2018-01-30 The Board Of Trustees Of The Leland Stanford Junior University Method for selecting agents that bind to transmembrane receptors in a conformationally selective manner
JP2021510733A (en) 2018-01-12 2021-04-30 ケーディーエーシー セラピューティクス，インコーポレーテッドＫｄａｃ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Combination of selective histone deacetylase 3 (HDAC3) inhibitor and immunotherapeutic agent for the treatment of cancer
EP3947419A4 (en) * 2019-04-01 2023-05-24 Rush University Medical Center Reagents and assays using modified integrin domains
US11100297B2 (en) * 2019-04-15 2021-08-24 International Business Machines Corporation Provision of natural language response to business process query

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
JPS6147500A (en) 1984-08-15 1986-03-07 Res Dev Corp Of Japan Chimera monoclonal antibody and its preparation
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (en) 1984-12-04 1986-06-21 Teijin Ltd Expression of hybrid antibody gene
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0264166B1 (en) 1986-04-09 1996-08-21 Genzyme Corporation Transgenic animals secreting desired proteins into milk
WO1988006592A1 (en) * 1987-02-26 1988-09-07 Dana-Farber Cancer Institute, Inc. Cloning of lfa-1
US5512660A (en) * 1987-05-04 1996-04-30 Dana Farber Cancer Institute, Inc. Purified ICAM-2 and fragment thereof
US5831036A (en) * 1987-05-04 1998-11-03 Dana Farber Cancer Institute Soluble fragments of human intercellular adhesion molecule-1
US5489533A (en) * 1987-05-04 1996-02-06 Dana Farber Cancer Institute Isolated nucleic acid molecules encoding ICAM-2
US5284931A (en) * 1987-05-04 1994-02-08 Dana Farber Cancer Institute Intercellular adhesion molecules, and their binding ligands
US5565550A (en) * 1987-05-04 1996-10-15 Dana Farber Cancer Institute Antibodies to ICAM-2, and fragments thereof
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5395929A (en) * 1987-12-15 1995-03-07 Dana Farber Cancer Institute Isolated nucleic acid encoding the alpha subunit of the human leukocyte adhesion receptor
EP0364690A3 (en) * 1988-08-23 1990-07-18 Dana Farber Cancer Institute The alpha-subunit of the mac-1 leukocyte adhesion receptor
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE68927933T2 (en) 1988-09-02 1997-08-14 Dyax Corp PRODUCTION AND SELECTION OF RECOMBINANT PROTEINS WITH DIFFERENT BINDING POINTS
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US6511664B1 (en) * 1989-03-09 2003-01-28 Dana Farber Cancer Institute Intercellular adhesion molecule—2 and its binding ligands
US6777191B1 (en) * 1989-03-16 2004-08-17 Center For Blood Research, Inc. Use of functional derivatives of the intercellular adhesion molecule ICAM-1 in diagnosis of viral infection
US6797270B1 (en) * 1989-03-16 2004-09-28 Center For Blood Research, Inc. Functional derivatives of the intercellular adhesion molecule ICAM-1 in anti-viral therapy
FR2646438B1 (en) 1989-03-20 2007-11-02 Pasteur Institut A METHOD FOR SPECIFIC REPLACEMENT OF A COPY OF A GENE PRESENT IN THE RECEIVER GENOME BY INTEGRATION OF A GENE DIFFERENT FROM THAT OR INTEGRATION
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
AU633958B2 (en) 1989-07-25 1993-02-11 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
NZ236792A (en) 1990-01-19 1993-05-26 Merck & Co Inc Recombinant human anti-cd18 antibody, murine 1b4 heavy or light chain variable region, dna, vectors, mammalian host and pharmaceutical compositions
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5393788A (en) 1990-07-10 1995-02-28 Smithkline Beecham Corporation Phenylalkyl oxamides
US5288854A (en) * 1990-11-28 1994-02-22 Center For Blood Research, Inc. Functional derivatives of ICAM-1 which are substantially capable of binding to LFA-1 but are substantially incapable of binding to MAC-1
ATE363532T1 (en) 1991-03-01 2007-06-15 Dyax Corp METHOD FOR PRODUCING BINDING MINIPROTEINS
US5460945A (en) * 1991-05-30 1995-10-24 Center For Blood Research, Inc. Device and method for analysis of blood components and identifying inhibitors and promoters of the inflammatory response
US5891841A (en) * 1991-06-11 1999-04-06 The Center For Blood Research, Inc. Methods of using intercellular adhesion molecule-3 (ICAM-3), antibodies thereto, and soluble fragments thereof
DE122004000008I1 (en) * 1991-06-14 2005-06-09 Genentech Inc Humanized heregulin antibody.
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
WO1993023526A1 (en) * 1992-05-21 1993-11-25 Center For Blood Research, Inc. A NOVEL RECEPTOR FOR α4 INTEGRINS AND METHODS BASED THEREON
AU687755B2 (en) * 1992-08-21 1998-03-05 Genentech Inc. Method for treating an LFA-1-mediated disorder
US5877295A (en) * 1992-09-30 1999-03-02 The Center For Blood Research Antibodies which bind a subpopulation of Mac-1 (CD11b/CD18) molecules which mediate neutrophil adhesion to ICAM-1 and fibrinogen
US5514555A (en) * 1993-03-12 1996-05-07 Center For Blood Research, Inc. Assays and therapeutic methods based on lymphocyte chemoattractants
US5470953A (en) * 1993-12-23 1995-11-28 Icos Corporation Human β2 integrin α subunit
GB2298520B (en) * 1995-03-03 1999-09-08 Hong Chen Fu In Heat sink device for integrated circuit
US5869046A (en) * 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) * 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5747035A (en) * 1995-04-14 1998-05-05 Genentech, Inc. Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
US6096871A (en) * 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5888765A (en) 1995-06-23 1999-03-30 President And Fellows Of Harvard College Endothelial-cell specific promoter
US6184223B1 (en) * 1995-10-27 2001-02-06 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
US5914112A (en) * 1996-01-23 1999-06-22 Genentech, Inc. Anti-CD18 antibodies in stroke
US5843712A (en) * 1996-06-06 1998-12-01 The Trustees Of Columbia University In The City Of New York Sindbis virus expression system for recombinant antibody production
IL130143A0 (en) * 1996-11-27 2000-06-01 Genentech Inc Humanized anti-CD11a antibodies
US6037454A (en) * 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
EP0998486B2 (en) * 1997-06-13 2012-02-01 Genentech, Inc. Protein recovery by chromatography followed by filtration upon a charged layer
US6572856B1 (en) * 1998-09-10 2003-06-03 The University Of Virginia Patent Foundation Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies
US6582698B1 (en) * 1999-03-19 2003-06-24 Genentech, Inc. Treatment method
MY122724A (en) 1999-04-13 2006-04-29 Mitsui Chemicals Inc Method for preparing living polymer in the presence of phosphazenium salt
US20010031260A1 (en) * 1999-12-14 2001-10-18 Genentech, Inc. Treatment method
JP3933847B2 (en) 2000-06-19 2007-06-20 ユニ・チャーム株式会社 Absorbent articles
WO2002004521A2 (en) * 2000-07-07 2002-01-17 California Institute Of Technology Proteins with integrin-like activity

Also Published As

Publication number Publication date
DE60140457D1 (en) 2009-12-24
US7160541B2 (en) 2007-01-09
US20100113742A1 (en) 2010-05-06
WO2002018583A3 (en) 2003-01-30
JP2004527217A (en) 2004-09-09
WO2002018583A2 (en) 2002-03-07
CA2417432A1 (en) 2002-03-07
US7674604B2 (en) 2010-03-09
EP1315812B1 (en) 2009-11-11
JP5113314B2 (en) 2013-01-09
US8241627B2 (en) 2012-08-14
CA2417432C (en) 2010-11-02
US20050260192A1 (en) 2005-11-24
US20050182244A1 (en) 2005-08-18
US7241869B2 (en) 2007-07-10
US7879577B2 (en) 2011-02-01
ATE448306T1 (en) 2009-11-15
US20110111528A1 (en) 2011-05-12
US20110305691A1 (en) 2011-12-15
EP1315812A2 (en) 2003-06-04
US7968284B2 (en) 2011-06-28
WO2002018583A9 (en) 2003-10-30
US20020123614A1 (en) 2002-09-05

Similar Documents

Publication Publication Date Title
AU2001287000A1 (en) Modified polypeptides stabilized in a desired conformation and methods for producing same
WO2006017325A3 (en) Aav vector compositions and methods for enhanced expression of immunoglobulins the same
WO2002004523A3 (en) Artificial antibody polypeptides
EP2221317A3 (en) PEGylated single domain antibodies (dAb)
DE69737683D1 (en) ANTIBODIES TO THE ED-B DOMAIN OF FIBRONECTIN, THEIR PREPARATION AND USES
WO1996017924A3 (en) Novel hedgehog-derived polypeptides
WO2002002783A3 (en) Expression vectors
IL181578A (en) Antibodies which are specifically immunoreactive with hedgehog interacting proteins and a hybridoma producing such antibodies
ATE177758T1 (en) SYNTHETIC PEPTIDES, ANTIBODIES AGAINST THEM AND THEIR USE
GR3019849T3 (en) Acute pancreatitis associated protein and means for the diagnosis of acute pancreatitis
PT1200561E (en) CLONE CELLULAR RECOMBINANT STABLE, ITS PRODUCTION AND UTILIZATION
WO2002079394A3 (en) Synthesis and use of glycodendrimer reagents
ECSP055849A (en) ANTIBODY ("11C7") ANTI-NOGO A AND ITS PHARMACEUTICAL USE
ATE234918T1 (en) MONOCLONAL ANTIBODIES AGAINST SOLUBLE TNF-ALPHA RECEPTORS P55 AND P75 AS WELL AS AGAINST TNF-ALPHA AND ITS ANALOGUES
WO2000001712A3 (en) Chemically modified proteins with a carbohydrate moiety
WO2004094615A3 (en) Prokaryotic collagen-like proteins and uses thereof
ATE408631T1 (en) CHIMERIC PROTEIN CONTAINING AN INTRAMOLECULAR CHAPERONE-LIKE SEQUENCE AND ITS APPLICATION TO INSULIN PRODUCTION
ATE331032T1 (en) GLUTAMINE: FRUCTOSE-6-PHOSPHATE AMIDOTRANSFERASE (GFAT), THEIR PRODUCTION AND USE
SE0002835D0 (en) Method and kit for production of monoclonal antibodies
TW200407428A (en) Method for the preparation of growth hormone and antagonist thereof having lower levels of isoform impurities thereof
DE59709495D1 (en) Antibodies and immunoassay for the detection of MIA
Velikson et al. Structural modeling of the pro-ocytocin-neurophysin precursor.
WO2001085937A3 (en) Regulator of g protein signalling (rgs8)
AU2003242344A1 (en) Translation templates and library thereof, proteins synthesized therefrom and protein library, constituents thereof, process for producing the same and method of using the same
WO2002010196A3 (en) Identification of a novel glutamine transporter